Scientists at Stanford University have made a significant breakthrough in the effort to produce Taxol, a vital chemotherapy drug, using yeast instead of relying solely on yew trees. Taxol, which is commonly used to treat ovarian, breast, and lung cancers, is traditionally extracted from the bark of yew trees, which grow slowly and are limited in their supply of the drug.
The research team, led by postdoctoral scholar Conor McClune, has identified key enzymes that help create Taxol. Enzymes are biological catalysts that speed up chemical reactions and play a crucial role in producing this complex drug. The team hopes that with the right enzymes, they can use industrial microbes like yeast as efficient production factories for Taxol.
For more than two decades, researchers have struggled to unlock the secrets of how yew trees produce Taxol, which has a complicated structure and is expensive to manufacture. The Stanford team’s innovative method involved examining the genes of yew trees. They stressed the plant samples to induce the production of defensive compounds, which included Taxol. After analyzing the cells, the scientists identified 22 genes, including eight new ones, that contribute to the drug’s formation.
One of the newly discovered genes, called FoTO1, plays a significant role in guiding the chemical reactions needed to produce Taxol’s precursor, baccatin III. Remarkably, the team found that the genes they identified allowed tobacco plants to generate baccatin III at levels even higher than what is found in yew trees.
While scientists had previously discovered 12 genes linked to Taxol production, the additional 10 genes are seen as vital pieces of the puzzle. With this knowledge, researchers are thrilled about the possibility of creating a sustainable way to manufacture Taxol without depleting natural yew tree populations.
In collaboration with scientists from the University of Copenhagen, the Stanford team has identified all the necessary enzymes needed to transform baccatin III into Taxol, leaving just two final steps to complete the process. If proven effective in further tests, these enzymes could be inserted into yeast strains, allowing for large-scale production of Taxol.
“We could really make a lot of this and no longer need the yew at all to get baccatin,” McClune commented on the potential of this research.
The implications of this discovery are significant, not only for Taxol production but also for the future of biosynthesis in pharmaceuticals. As the researchers continue to investigate other plants, they hope to uncover more enzymes that could lead to innovative ways to produce various beneficial compounds.
With these advancements, the team stands on the brink of transforming cancer treatment, providing hope for a more efficient and sustainable supply of vital medications like Taxol.
-Rashmi Kumari
